Autonomix Medical, Inc. (AMIX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-01-16

Key Insights

Autonomix Medical, Inc. has received a deficiency letter from Nasdaq notifying the company that its common stock has closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market.
The company has been provided an initial period of 180 calendar days, or until July 13, 2026, to regain compliance with the minimum bid price rule. If the company is unable to regain compliance by the deadline, it may be afforded a second 180-day compliance period.
The company intends to monitor the closing bid price of its common stock and may consider options to regain compliance, such as a reverse stock split, but there is no assurance it will be able to do so.

Want the newest filings?

This analysis covers the filing from 2026-01-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-09

Autonomix Medical presented new positive subgroup data from its PoC study on pain relief in pancreatic cancer patients across all disease stages, suggesting a potential significant therapeutic benefit.
The company posted an updated corporate presentation, providing investors with the latest developments and financial information.
As an emerging growth company, Autonomix Medical has the flexibility to comply with new or revised financial accounting standards, which could impact its future financial reporting.

Other reports for Autonomix Medical, Inc.

Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.